UK markets open in 7 hours 20 minutes
NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.40 -0.50 (-0.02%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,312.20 -902.50 (-1.61%)
Evolus, Inc. (EOLS)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Loading interactive chart…
- Zacks
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
- Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif., May 20, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville.
- GuruFocus.com
Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
On May 14, 2024, David Gill, Director at Evolus Inc (NASDAQ:EOLS), executed a sale of 10,361 shares of the company.
© 2024 Yahoo. All rights reserved.